BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
BiomX (PHGE) announced positive results from Part 1 of its Phase 1b/2a trial for BX004 targeting lung infections in cystic fibrosis (CF) patients. The treatment showed a significant bacterial load reduction of over 90% compared to placebo and no safety concerns. Enrollment for Part 2 is ongoing, with results expected in Q3 2023. Financially, BiomX reported a cash balance of $34.3 million as of Dec 31, 2022, down from $63.1 million the previous year. The company estimates its cash runway extends through mid-2024, supported by a $7.5 million private placement and a $5 million award from the Cystic Fibrosis Foundation.
- Significant reduction of over 90% in bacterial load in CF patients treated with BX004 compared to placebo.
- No safety events related to treatment with BX004.
- Cash runway extended through at least mid-2024, allowing continued development of BX004.
- Cash balance decreased from $63.1 million to $34.3 million year-over-year.
- Net loss for 2022 of $28.3 million, though improved from $36.2 million in 2021.
Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”)
Patient Enrollment Continues in Part 2 of Phase 1b/2a Trial with Results Expected in Third Quarter of 2023
Cash Runway Through at Least Mid-2024
Company Will Host a Conference Call and Webcast Today at 8:00 am ET
CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.
“2023 is shaping up to be a very exciting year for our company, and the field of phage therapeutics. Based on the highly encouraging results from Part 1 of our ongoing Phase 1b/2a trial, we believe the BX004 program is fast-emerging as one of the most promising new treatments for CF patients suffering from chronic Pseudomonas aeruginosa infections,” said Jonathan Solomon, Chief Executive Officer of BiomX. “BX004 not only demonstrated excellent safety, but also resulted in notable reductions in bacterial load in the lungs of CF patients. We have already dosed patients in Part 2 of the Phase 1b/2a study and remain on track to report results in the third quarter of 2023.
“There is a growing body of clinical evidence, including data from compassionate use programs, that phage-based therapies such as BX004 may represent an important new modality for treating the thousands of CF patients who suffer from chronic, life-threatening lung infections. In Part 2, we will dose at least 24 CF patients with BX004 twice a day and over a longer, 10-day treatment period. Results from Part 2 will provide important additional safety data and should provide clinical insights, particularly regarding the reduction in Pseudomonas aeruginosa bacterial burden, that will help us advance BX004 into pivotal testing. Other clinical endpoints including CF patients reported outcomes and lung function also will be assessed.”
Clinical Program Updates
Cystic Fibrosis (BX004)
- In February 2023, BiomX announced positive results from Part 1 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa (or P. aeruginosa) in patients with cystic fibrosis. Highlights from the data included:
- No safety events related to treatment with BX004
- Mean P. aeruginosa colony forming units (CFU) at Day 15 (compared to baseline): -1.42 log10 CFU/g (BX004) vs. -0.28 log10 CFU/g (placebo), a reduction of greater than
90% . This reduction was seen on top of standard of care inhaled antibiotics - Phages were detected in all patients treated with BX004 during the dosing period, including in several patients up to Day 15 (one week after end of therapy); no phages were detected in patients receiving placebo
- There was no emerging bacterial resistance to BX004 during or after treatment with BX004
- As expected, likely due to the short course of therapy, there was no detectable effect on % predicted FEV1
- Dosing of patients in Part 2 of the Phase 1b/2a trial has been initiated; results from Part 2 are expected in the third quarter of 2023.
- BX004 is being developed for the treatment of chronic respiratory infections caused by P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. The Phase 1b/2a trial is composed of two parts. Part 1 of the study evaluated the safety, pharmacokinetics, and microbiologic/clinical activity of BX004 in nine CF patients in a single ascending dose and multiple dose design. Part 2 of the study will evaluate the safety and efficacy of BX004 in at least 24 CF patients randomized to a treatment or placebo cohort in a 2:1 ratio.
- As previously announced, BiomX has received a Therapeutics Development Award of up to
$5 million from the Cystic Fibrosis Foundation (“CF Foundation”). The award is structured as an equity investment in which the CF Foundation has agreed to purchase up to$5 million of BiomX common stock across two separate tranches. The first tranche was received on December 21, 2021, with the CF Foundation making an initial equity investment of$3 million . Following the results from Part 1 of the ongoing Phase 1b/2a trial, the CF Foundation is making its second tranche investment of$2 million through its participation in the Company’s recently announced$7.5 million private placement.
Atopic Dermatitis (BX005)
- The Company is collaborating with Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, supporting a range of pre-clinical activities to move this program forward and working on evaluating timelines for a clinical trial.
RECENT CORPORATE HIGHLIGHTS
- In February 2023, the Company announced a
$7.5 million private placement with a select group of institutional and individual investors, including existing investors OrbiMed and the Cystic Fibrosis Foundation. The financing is expected to close in two parts. The first closing for gross proceeds of$1.5 million occurred in February 2023. The second closing for the remaining Securities, which is contingent upon approval by the Company's stockholders in accordance with NYSE American rules, is expected to take place in the second quarter of 2023. BiomX expects to use the net proceeds from the PIPE, together with existing cash and cash equivalents, to fund clinical development of BX004 for the treatment of lung infections in patients with CF, the development of other programs, and research activities as well as working capital and other general corporate purposes.
Fourth Quarter and Full Year 2022 Financial Results
- Cash balance, short-term deposits and restricted cash as of December 31, 2022, were
$34.3 million , compared to$63.1 million as of December 31, 2021. The decrease was primarily due to net cash used in operating activities. Following the close of the fourth quarter of 2022, the Company raised$7.5 million in gross proceeds through a private placement,$6 million of which are contingent upon shareholders’ approval. Inclusive of net proceeds from the private placement, the Company estimates its cash runway is sufficient to fund operations through at least mid-2024.
- Research and development (“R&D”) expenses, net were
$16.2 million for the year ended December 31, 2022, compared to$22.7 million for the prior year. The decrease was primarily due to a decrease in salaries and related expenses and stock-based compensation expenses due to a reduction in workforce, as a result of a corporate restructuring; as well as discontinuing pausing the development of BX003, our product candidate for inflammatory bowel disease and delaying the development of BX005, our product candidate for atopic dermatitis.
- General and administrative expenses were
$9.5 million for the year ended December 31, 2022, compared to$11.3 million for the prior year. The decrease was primarily due to a decrease in salaries and related expenses and stock-based compensation expenses due to a reduction in workforce, as well as a decrease in recruitment and employee related expenses, both as a result of a corporate restructuring.
- Net loss for 2022 was
$28.3 million , compared to$36.2 million for the prior year.
- Net cash used in operating activities for the year ended December 31, 2022 was
$29.1 million , compared to$27.6 million for the same period in 2021.
Conference Call and Webcast Information
BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for 2022. To participate in the conference, please dial 1-877-407-0724 (U.S.), 1-809-406-247 (Israel), or 1-201-389-0898 (International). A live and archived webcast of the call will be available on the Investors section of the Company’s website at www.biomx.com, the content of which does not form a part of this press release.
About BiomX
BiomX is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria that target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
Safe Harbor
This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX discusses the potential safety or efficacy of BX004, the expected timing of Part 2 of the Phase 1b/2a study and the potential of targeted phage therapy to treat infections in CF patients, as well as other when it refers to other programs, such as the program to treat Atopic Dermatitis, BiomX is making forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2022 and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements
| BIOMX INC. | ||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||
| (USD in thousands, except share and per share data) | ||||||||
| As of December 31, | ||||||||
| 2022 | 2021 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | 31,332 | 62,099 | ||||||
| Restricted cash | 962 | 996 | ||||||
| Short-term deposits | 2,000 | - | ||||||
| Other current assets | 2,587 | 3,543 | ||||||
| Total current assets | 36,881 | 66,638 | ||||||
| Non-current assets | ||||||||
| Operating lease right-of-use assets | 3,860 | 4,139 | ||||||
| Property and equipment, net | 4,790 | 5,694 | ||||||
| Intangible assets, net | - | 1,519 | ||||||
| Total non-current assets | 8,650 | 11,352 | ||||||
| 45,531 | 77,990 | |||||||
| As of December 31, | ||||||||
| 2022 | 2021 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Trade account payables | 820 | 2,795 | ||||||
| Current portion of lease liabilities | 687 | 819 | ||||||
| Contract liability | - | 1,976 | ||||||
| Other account payables | 2,150 | 5,453 | ||||||
| Current portion of long-term debt | 4,282 | - | ||||||
| Total current liabilities | 7,939 | 11,043 | ||||||
| Non-current liabilities | ||||||||
| Contract liability | 1,976 | - | ||||||
| Long-term debt, net of current portion | 10,591 | 14,410 | ||||||
| Operating lease liabilities, net of current portion | 3,798 | 4,787 | ||||||
| Other liabilities | 188 | 215 | ||||||
| Total non-current liabilities | 16,553 | 19,412 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Preferred Stock, | - | - | ||||||
| Common stock, | 2 | 2 | ||||||
| Additional paid in capital | 157,838 | 156,017 | ||||||
| Accumulated deficit | (136,801 | ) | (108,484 | ) | ||||
| Total Stockholders’ equity | 21,039 | 47,535 | ||||||
| 45,531 | 77,990 | |||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
| (USD in thousands, except share and per share data) | ||||||||
| Year ended December 31, | ||||||||
| 2022 | 2021 | |||||||
| Research and development (“R&D”) expenses, net | 16,244 | 22,676 | ||||||
| Amortization of intangible assets | 1,519 | 1,519 | ||||||
| General and administrative expenses | 9,456 | 11,267 | ||||||
| Operating loss | 27,219 | 35,462 | ||||||
| Other income | (134 | ) | - | |||||
| Interest expenses | 2,069 | 699 | ||||||
| Financial income, net | (902 | ) | (2 | ) | ||||
| Loss before tax | 28,252 | 36,159 | ||||||
| Tax expenses | 65 | 67 | ||||||
| Net Loss | 28,317 | 36,226 | ||||||
| Basic and diluted loss per share of Common Stock | 0.95 | 1.39 | ||||||
| Weighted average number of shares of Common Stock outstanding, basic and diluted | 29,854,003 | 26,007,947 | ||||||
BiomX Contacts
Investor Relations:
LifeSci Advisors, LLC
John Mullaly
(617)-698-9253
jmullaly@lifesciadvisors.com
BiomX, Inc.
Anat Primovich
Corporate Project Manager
+972 (50) 697-7228
anatp@biomx.com
Source: BiomX Inc.
FAQ
What were the results of BX004 in the Phase 1b/2a trial for cystic fibrosis patients?
When will the results for Part 2 of the BX004 trial be announced?
How much cash does BiomX have as of the end of 2022?
What is the financial outlook for BiomX in 2024?
What support has BiomX received from the Cystic Fibrosis Foundation?
